The approval encompasses two distinct age groups: adults 50 to 65 received traditional FDA approval, while the 65-and-older population secured accelerated approval contingent on Moderna conducting an additional clinical trial in that demographic. The decision positions mFlusiva as an important new option in the fight against seasonal influenza, which hospitalizes hundreds of thousands of Americans annually and causes tens of thousands of deaths, with young children and older adults facing the highest risk of severe illness.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors,” Moderna CEO Stephane Bancel said in a statement. “This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation.”

Clinical Trial Data Demonstrates Superior Efficacy

The new vaccine demonstrated approximately 27% greater effectiveness during the 2024-25 respiratory virus season compared to standard flu shots in Moderna’s late-stage clinical trial. The study enrolled more than 40,000 adults aged 50 and older, providing substantial evidence for the vaccine’s benefits despite the traditional flu shot’s already variable effectiveness, which ranges from 22% to 56% according to Mayo Clinic data.

Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children’s Hospital, acknowledged the current limitations of flu vaccine effectiveness. “We wish it were higher, quite frankly,” Levy said, emphasizing the need for improved influenza prevention tools.

Side effects observed in clinical trials included injection-site reactions such as pain, tenderness and swollen lymph nodes, along with systemic responses including fatigue, headache, muscle or joint pain, nausea or vomiting, and fever. These adverse effects align with typical vaccine reactions and did not raise significant safety concerns during the regulatory review process.

mRNA Technology Offers Faster Production Timeline

The messenger RNA platform used in mFlusiva provides a critical advantage over conventional flu vaccine manufacturing: dramatically reduced production time between strain selection and public availability. Moderna stated that its mRNA flu vaccine requires just two to three months from strain selection to rollout, compared with approximately six months for traditional flu shots that rely on egg-based or cell-based production methods.

This shortened timeline could allow for a closer match between the immunity conferred by vaccines and the season’s circulating influenza strains, addressing a longstanding challenge in flu vaccine development. For vaccines previously on the market, experts select flu strains for each fall’s seasonal vaccines during the preceding February, creating a substantial lag that can reduce vaccine effectiveness if influenza viruses evolve significantly during the intervening months.

“If you’re choosing the strain half a year before, how good can we be at sharpshooting?” Levy asked, highlighting the inherent difficulty of predicting which flu strains will dominate months in advance.

Contentious Approval Process Reflects Regulatory Tensions

The vaccine’s journey to approval encountered significant turbulence in February when the FDA issued Moderna a rare refusal to file letter, citing concerns with the design of the phase 3 trial despite what the company characterized as previous conflicting feedback within the agency. The FDA specifically took issue with Moderna’s use of a standard-dose flu vaccine as the comparator arm in its trial, suggesting the company had not used “the best-available standard of care” since the Centers for Disease Control and Prevention recommends high-dose flu vaccines for adults 65 and older.

Moderna publicly challenged the FDA’s decision, noting that the agency had not flagged the trial design as problematic when previously discussing study protocols. The FDA, whose Center for Biologics Evaluation and Research was at the time headed by controversial director Vinay Prasad, reversed course approximately two weeks later and agreed to review the shot.

In June, the FDA’s independent vaccine advisory panel-composed of nine physicians and vaccine scientists-unanimously voted that mFlusiva’s benefits outweighed its risks across both age groups. The Vaccines and Related Biological Products Advisory Committee’s unanimous recommendation provided critical momentum toward final approval.

Political Opposition to mRNA Technology Persists

The approval arrives amid sustained political opposition to mRNA vaccine technology from the current administration despite the platform’s proven success during the COVID-19 pandemic. Although the record-speed development of mRNA-based COVID-19 vaccines was a chief accomplishment of President Donald Trump‘s first term, his second administration has withdrawn support for mRNA technology in infectious diseases.

The US Department of Health and Human Services canceled 22 projects worth approximately $500 million focused on mRNA vaccine development in August 2025. HHS Secretary Robert F. Kennedy Jr.-an anti-vaccine activist-claimed against scientific evidence that “these vaccines fail to protect effectively against upper respiratory infections like COVID and flu,” and has repeatedly characterized COVID vaccines as “the deadliest vaccine ever made.”

Despite this political headwind, the FDA’s career scientists and independent advisors maintained their assessment that mRNA vaccine benefits outweigh risks based on clinical trial data and real-world evidence.

Broader mRNA Vaccine Pipeline Advances

Moderna uses mRNA technology in its COVID-19 vaccines, as does drugmaker Pfizer, which also has mRNA-based flu vaccines in development. An mRNA-based vaccine from Moderna targeting both COVID-19 and influenza was approved in Europe earlier this year, demonstrating the technology’s expanding global footprint and potential for combination vaccines.

Moderna expects to have mFlusiva available this fall, positioning the vaccine for the upcoming respiratory virus season. The approval represents the company’s fourth FDA clearance and establishes a new category of influenza prevention tools leveraging the mRNA platform that proved transformative during the pandemic.

The Infectious Diseases Society of America emphasizes that flu remains a significant public health challenge requiring continued innovation in prevention strategies. With mFlusiva now available as an option for older adults, healthcare providers will have an additional tool that offers improved effectiveness and more agile manufacturing compared to traditional approaches.

The post FDA Approves Nation’s First mRNA-Based Flu Vaccine for Adults 50 and Older appeared first on The Daily Update.